SYDNEY: Nanoveu Limited has signed distribution agreements for the it’s antiviral protection products with Sanyo Trading Company Limited for the Thai and Malaysian markets.

Sanyo Trading is a major corporation listed on the Tokyo Stock Exchange which provides trading services, managing the import and export of rubber, chemicals, machinery and other scientific and industrial products.

Through the agreements, Sanyo will look to leverage its extensive contacts in the Asia-Pacific region and will look to distribute a number of Nanoveu’s products to groups including hospitals, banks, schools and shopping malls.

Nanoveu’s antiviral technology has been independently demonstrated to be a highly effective agent for the eradication of viruses. The technology has been proven to eliminate 99.99%1of OC43, a viral strain affecting humans that is also a surrogate for COVID-19, in 30 minutes. The antiviral protection has also been validated against other bacteria and viruses including e.Coli, Influenza A (subtype H3N2), and coronavirus MHV-A592.

Commenting on the agreement, Sandy Yew, Sales Director of Sanyo Trading Pte. Ltd. said: “The spread of disease is a major focus for many countries, including those in the Asia-Pacific region. We are excited about brining Nanoveu’s Nanoshield products to our customers, partners and distributors as it represents a credible and proven method of stemming the spread of harmful viruses and bacteria.”

Nanoveu Executive Chairman and CEO Alfred Chong added: “Founded in 1947, Sanyo is a name that many consumers in the region are familiar with. We are proud that we have been elected to be a partner for such a reputable company which possesses both the reach and capability to distribute our products internationally.”